A comparative analysis of 1.5-stage stem hybrid fixation versus two-stage exchange arthroplasty for periprosthetic hip infection : is a 1.5-stage exchange equivalent?
Jesus M Villa, Shayan Hosseinzadeh, Katherine Rajschmir, Jorge Manrique-Succar, Carlos A Higuera-Rueda, Aldo M Riesgo
{"title":"A comparative analysis of 1.5-stage stem hybrid fixation versus two-stage exchange arthroplasty for periprosthetic hip infection : is a 1.5-stage exchange equivalent?","authors":"Jesus M Villa, Shayan Hosseinzadeh, Katherine Rajschmir, Jorge Manrique-Succar, Carlos A Higuera-Rueda, Aldo M Riesgo","doi":"10.1302/0301-620X.107B6.BJJ-2024-1088.R1","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Two-stage exchange arthroplasty is frequently used to treat periprosthetic hip infection. Nevertheless, particularly in high-risk patients, there has been increased attention towards single-surgery options such as 1.5-stage exchange. Therefore, we sought to compare 1.5- and two-stage patients and determine: 1) baseline demographic details, comorbidities, infection, surgical, and inpatient characteristics; 2) re-revision rates and causes, hip pain and implant loosening of surviving implants, success/failure according to the Musculoskeletal Infection Society (MSIS) outcome reporting tool, and mortality at latest follow-up; and 3) whether the type of surgery (1.5- vs two-stage) is a re-revision predictor.</p><p><strong>Methods: </strong>We undertook a retrospective review of 73 patients who underwent either 1.5-stage stem hybrid fixation (n = 43) or two-stage exchange hip arthroplasty (n = 30) at a single institution (March 2019 to May 2023). Demographic information and variables of interest were compared between groups. Predictors of re-revision were assessed with logistic regression. The mean follow-up was 454 days (23 to 1,620).</p><p><strong>Results: </strong>Our cohorts were not significantly different, except for a higher proportion of 1.5-stage patients classified as American Society of Anesthesiologists (ASA) grade III or IV (77% vs 50%; p = 0.025). There were more prior revisions among 1.5-stage patients (mean 1.5 vs 0.7; p = 0.012), whereas mean length of follow-up and mean operating time were significantly longer among two-stage patients (650 vs 317 days, p = 0.002; and 501.3 (360 to 660) vs 267.2 mins (150 to 420), p < 0.001, respectively). In the 1.5-stage group, there was a significantly higher proportion of periprosthetic infections as a cause of re-revision (80% vs 0%; p = 0.011). Postoperative success or failure (MSIS outcome) and mortality rates were not statistically significantly different. The type of surgery was not a significant re-revision predictor.</p><p><strong>Conclusion: </strong>Our preliminary data suggest that our selective prescription of 1.5-stage revision was associated with significantly more re-revisions due to infection when compared with two-stage patients. We acknowledge the potential benefits of the 1.5-stage strategy, especially among high-risk patients, as it involves a single operation; however, higher reinfection rates must be considered when counselling these patients.</p>","PeriodicalId":48944,"journal":{"name":"Bone & Joint Journal","volume":"107-B 6 Supple B","pages":"62-69"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone & Joint Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1302/0301-620X.107B6.BJJ-2024-1088.R1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Two-stage exchange arthroplasty is frequently used to treat periprosthetic hip infection. Nevertheless, particularly in high-risk patients, there has been increased attention towards single-surgery options such as 1.5-stage exchange. Therefore, we sought to compare 1.5- and two-stage patients and determine: 1) baseline demographic details, comorbidities, infection, surgical, and inpatient characteristics; 2) re-revision rates and causes, hip pain and implant loosening of surviving implants, success/failure according to the Musculoskeletal Infection Society (MSIS) outcome reporting tool, and mortality at latest follow-up; and 3) whether the type of surgery (1.5- vs two-stage) is a re-revision predictor.
Methods: We undertook a retrospective review of 73 patients who underwent either 1.5-stage stem hybrid fixation (n = 43) or two-stage exchange hip arthroplasty (n = 30) at a single institution (March 2019 to May 2023). Demographic information and variables of interest were compared between groups. Predictors of re-revision were assessed with logistic regression. The mean follow-up was 454 days (23 to 1,620).
Results: Our cohorts were not significantly different, except for a higher proportion of 1.5-stage patients classified as American Society of Anesthesiologists (ASA) grade III or IV (77% vs 50%; p = 0.025). There were more prior revisions among 1.5-stage patients (mean 1.5 vs 0.7; p = 0.012), whereas mean length of follow-up and mean operating time were significantly longer among two-stage patients (650 vs 317 days, p = 0.002; and 501.3 (360 to 660) vs 267.2 mins (150 to 420), p < 0.001, respectively). In the 1.5-stage group, there was a significantly higher proportion of periprosthetic infections as a cause of re-revision (80% vs 0%; p = 0.011). Postoperative success or failure (MSIS outcome) and mortality rates were not statistically significantly different. The type of surgery was not a significant re-revision predictor.
Conclusion: Our preliminary data suggest that our selective prescription of 1.5-stage revision was associated with significantly more re-revisions due to infection when compared with two-stage patients. We acknowledge the potential benefits of the 1.5-stage strategy, especially among high-risk patients, as it involves a single operation; however, higher reinfection rates must be considered when counselling these patients.
期刊介绍:
We welcome original articles from any part of the world. The papers are assessed by members of the Editorial Board and our international panel of expert reviewers, then either accepted for publication or rejected by the Editor. We receive over 2000 submissions each year and accept about 250 for publication, many after revisions recommended by the reviewers, editors or statistical advisers. A decision usually takes between six and eight weeks. Each paper is assessed by two reviewers with a special interest in the subject covered by the paper, and also by members of the editorial team. Controversial papers will be discussed at a full meeting of the Editorial Board. Publication is between four and six months after acceptance.